Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement